Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 499Neoplasms 381Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 311Melanoma 309Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 284Brain Neoplasms 276Lymphoma 271Lung Neoplasms 270Recurrence 266Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Myelodysplastic Syndromes 208Glioma 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Camurati-Engelmann Syndrome × Clear all
NCT02065362 2026-01-29

TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

Baylor College of Medicine

Phase 1 Active not recruiting
14 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Camurati-Engelmann Syndrome

NCT00889954 2018-09-18

HERCREEM

Baylor College of Medicine

Phase 1 Completed
20 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡